Biodesix Inc.
Biodesix Inc. (BDSX): 8 pipeline candidates · ~9 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.9 months
D/E 9.36 · 0% dilution
Lead: Approved
8 candidates
N/A
3 buys · 15 sells (180d)
A transparent, data-derived signal for Biodesix Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$156.0M
Cash
$25.7M
Quarterly Burn
$10.2M
Runway
8.9 mo
Revenue
$25.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| genestrat ddpcr | Approved |
| genestrat ngs | Approved |
| nodify cdt | Approved |
| nodify xl2 | Approved |
| primary immune response | Preclinical |
| risk of recurrence | Preclinical |
| veristrat | Approved |
| xl2 | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
35
Total value held
$22.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 510,322 | $7.4M |
| marshall wace, llp | 141,636 | $2.1M |
| stempoint capital lp | 140,008 | $2.0M |
| essex investment management co llc | 132,086 | $1.9M |
| trexquant investment lp | 69,601 | $1.0M |
| geode capital management, llc | 49,998 | $726K |
| two sigma investments, lp | 45,231 | $656K |
| perkins capital management inc | 44,783 | $649K |
| sei investments co | 43,024 | $624K |
| legato capital management llc | 41,174 | $597K |
Showing top 10 of 35 institutional holders of Biodesix Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Biodesix Inc.'s pipeline?
Biodesix Inc. (BDSX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Biodesix Inc.'s lead drug candidate?
Biodesix Inc.'s most advanced tracked candidate is genestrat ddpcr (Approved) for Lung cancer mutation detection.
What is Biodesix Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Biodesix Inc. has approximately 8.9 months of cash runway.
What is Biodesix Inc.'s market capitalization?
Biodesix Inc.'s market capitalization is approximately $156.0M.
Who is the CEO of Biodesix Inc.?
Mr. Scott Hutton is the chief executive officer of Biodesix Inc. (BDSX).
Get the full picture on Biodesix Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.